Boston, October 14, 2025
News Summary
British biotech CellCentric is establishing a new office in Boston, marking a strategic move for its U.S. expansion. This facility will enhance clinical development and support regulatory planning for its lead asset, inobrodib, which is approaching late-stage trials. The choice of Boston, a renowned life sciences hub, aims to strengthen the company’s presence in drug development for multiple myeloma and other cancers. Recruitment for specialized roles is ongoing, with plans to bolster the executive team.
Boston — British biotech CellCentric is opening a new office in Boston as part of a broader U.S. expansion while its lead drug candidate advances toward late-stage development.
Key facts
British biotech CellCentric is opening a new office in Boston. The new office is part of CellCentric’s expansion into the U.S. The move positions the company in a major life sciences hub as the company advances its lead asset toward later clinical phases and prepares for larger-scale trials and regulatory steps.
Why Boston and what the office will do
Boston is recognized as a global hub for biotechnology and pharmaceutical innovation. The new U.S. hub will be used to accelerate clinical development and regulatory planning for the company’s lead asset and to support broader U.S.-based operations. The new U.S. hub will facilitate the accelerated approval and phase 3 studies of inobrodib.
CellCentric’s operations in the U.S. will focus on drug development for multiple myeloma and other cancers. To support that focus, the new office will leverage the strong talent pool on the East Coast to bolster the company’s team. Recruiting efforts are underway, with priorities set on staff experienced in later-stage oncology programs.
Hiring and leadership
Recruiting efforts are underway for positions with experience in later-stage multiple myeloma drug development. Key roles being filled include regulatory, clinical data management, statistics, and program management specialists. In addition, CellCentric plans to appoint new executive team members, including a chief business officer and chief financial officer based in the U.S. These hires are intended to provide local leadership for clinical, regulatory and commercial planning.
Clinical program details
CellCentric’s lead asset, inobrodib, is progressing to late-stage clinical development. Inobrodib is an oral small molecule targeting transcriptional regulators p300 and CREB-binding protein linked to cancer. The drug is currently undergoing phase 1/2 trials in blood cancers and advanced solid tumors and has received orphan drug designation from the FDA for use in multiple myeloma as of June 2023. These developments are central to the company’s rationale for strengthening its U.S. presence and advancing phase 3 planning.
Timing and company footprint
The expansion has been in planning since the beginning of 2025. CellCentric already maintains a U.K. footprint, and CellCentric also has existing offices in Cambridge and Manchester in the U.K. The company has described a strong U.S. presence as important for its clinical and commercial strategy, noting that the company emphasizes U.S. presence as critical for its primary clinical and commercial market despite challenges posed by the current administration.
Operational focus going forward
Operational activities at the Boston office will center on supporting phase 3 readiness for inobrodib, building regulatory submissions and clinical trial operations, and expanding relationships with U.S.-based investigators and partners. The company will continue early-stage work conducted in existing U.K. sites while shifting late-stage program management and commercial planning functions to the new U.S. hub.
Context
Boston’s established academic centers, clinical trial networks and biotech talent pool make it a frequent choice for companies seeking to scale clinical programs in oncology. For CellCentric, locating a U.S. office in Boston aims to streamline late-stage development activities and prepare the company for larger, U.S.-based trials and regulatory steps. The orphan drug status from the U.S. regulatory authority supports priority planning for multiple myeloma, and the company’s stated hiring and leadership appointments are intended to align resources for accelerated program delivery.
FAQ
What is the immediate news?
British biotech CellCentric is opening a new office in Boston.
Why is the office being opened?
The new office is part of CellCentric’s expansion into the U.S.
What is the company’s lead asset doing?
CellCentric’s lead asset, inobrodib, is progressing to late-stage clinical development.
Why choose Boston?
Boston is recognized as a global hub for biotechnology and pharmaceutical innovation.
How will the U.S. hub support inobrodib?
The new U.S. hub will facilitate the accelerated approval and phase 3 studies of inobrodib.
What will the U.S. operations focus on?
CellCentric’s operations in the U.S. will focus on drug development for multiple myeloma and other cancers.
How will the company staff the new office?
The new office will leverage the strong talent pool on the East Coast to bolster the company’s team.
What roles are being recruited?
Recruiting efforts are underway for positions with experience in later-stage multiple myeloma drug development.
Which specific positions are being filled?
Key roles being filled include regulatory, clinical data management, statistics, and program management specialists.
Will new executives be based in the U.S.?
CellCentric plans to appoint new executive team members, including a chief business officer and chief financial officer based in the U.S.
When was the expansion planned?
The expansion has been in planning since the beginning of 2025.
What is inobrodib?
Inobrodib is an oral small molecule targeting transcriptional regulators p300 and CREB-binding protein linked to cancer.
What regulatory status does inobrodib have?
Inobrodib has received orphan drug designation from the FDA for use in multiple myeloma as of June 2023.
What trials are ongoing?
The drug is currently undergoing phase 1/2 trials in blood cancers and advanced solid tumors.
Where are CellCentric’s other offices?
CellCentric also has existing offices in Cambridge and Manchester in the U.K.
Why emphasize a U.S. presence?
The company emphasizes U.S. presence as critical for its primary clinical and commercial market despite challenges posed by the current administration.
Quick reference table
| Topic | Fact |
|---|---|
| Office opening | British biotech CellCentric is opening a new office in Boston. |
| Expansion scope | The new office is part of CellCentric’s expansion into the U.S. |
| Lead asset status | CellCentric’s lead asset, inobrodib, is progressing to late-stage clinical development. |
| Location rationale | Boston is recognized as a global hub for biotechnology and pharmaceutical innovation. |
| Clinical support aim | The new U.S. hub will facilitate the accelerated approval and phase 3 studies of inobrodib. |
| Therapeutic focus | CellCentric’s operations in the U.S. will focus on drug development for multiple myeloma and other cancers. |
| Hiring focus | Recruiting efforts are underway for positions with experience in later-stage multiple myeloma drug development. |
| Key hires | Key roles being filled include regulatory, clinical data management, statistics, and program management specialists. |
| Executive staffing | CellCentric plans to appoint new executive team members, including a chief business officer and chief financial officer based in the U.S. |
| Planning timeline | The expansion has been in planning since the beginning of 2025. |
| Drug description | Inobrodib is an oral small molecule targeting transcriptional regulators p300 and CREB-binding protein linked to cancer. |
| Regulatory status | Inobrodib has received orphan drug designation from the FDA for use in multiple myeloma as of June 2023. |
| Trial status | The drug is currently undergoing phase 1/2 trials in blood cancers and advanced solid tumors. |
| Existing offices | CellCentric also has existing offices in Cambridge and Manchester in the U.K. |
| Market strategy | The company emphasizes U.S. presence as critical for its primary clinical and commercial market despite challenges posed by the current administration. |
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Fierce Biotech: British Biotech CellCentric Expands in Boston
- Boston Globe: Lab Space in Boston
- CoStar: Biotech Firm Leases Space at Boston Skyscraper
- Wikipedia: Boston
- Stat News: Boston Lab Market for Biotech
Author: STAFF HERE BOSTON WRITER
BOSTON STAFF WRITER The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
